Ibuprofen
(Synonyms: 布洛芬; (±)-Ibuprofen) 目录号 : GC17863
An NSAID and non-selective COX inhibitor
Cas No.:15687-27-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
| Cell experiment [1]: | |
|
Cell lines |
p53 wild-type or p53-deficient human colon cancer HCT-116 cell lines |
|
Preparation method |
The solubility of this compound in DMSO is > 10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
|
Reacting condition |
0-1000 μM; 24 h (cell cycle distribution) or 72 h (apoptosis). |
|
Applications |
In a colony forming assay, S-ibuprofen and R-ibuprofen exhibited significantly higher anti-proliferative effects in the p53wt cell line than in the p53-deficient HCT-116 cells. In HCT-116 p53wt cells, 800-1000 μM S-ibuprofen and R-ibuprofen reduced cells in the S and G2/M phases and significantly increased the number of cells in the G0/G1-phase. 800-1000 μM S- and R-ibuprofen also significantly increased apoptosis. |
| Animal experiment [1]: | |
|
Animal models |
Athymic nude mice xenografted with implanted subcutaneously with HCT-116 p53wt and p53-/- colon cancer cells |
|
Dosage form |
five days a week intraperitoneally with 15 mg/kg/day, suspended in PBS (pH 7), 5 weeks |
|
Application |
Compared with the tumour volumes of untreated mice, R-ibuprofen significantly reduced the growth of p53wt expressing xenografts. S-ibuprofen also reduced the growth of p53wt expressing xenografts. But only a small and non-significant inhibition of HCT-116 p53-/- tumour growth after S- or R-ibuprofen treatment. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1]. Janssen A, Schiffmann S, Birod K, et al. p53 is important for the anti-proliferative effect of ibuprofen in colon carcinoma cells. Biochem Biophys Res Commun, 2008, 365(4): 698-703. |
|
Ibuprofen is an inhibitor of cyclooxygenase 1 and cyclooxygenase 2 with IC50 values of 12 and 80 μM, respectively [1].
Cyclooxygenase (COX) is an enzyme that is responsible for the formation of prostaglandins, prostacyclin and thromboxane.
In HCT-116 p53wt or HCT-116 p53-/-colon carcinoma cell lines, S- and R-ibuprofen induced apoptosis and blocked cell cycle is in part dependent on p53. The anti-proliferative effects were significantly higher in the p53wt cell line than in the p53-deficient cells [2].
In nude mice model bearing HCT-116 p53wt and p53-/- xenografts, R-ibuprofen significantly inhibited the growth of p53wt expressing xenografts and only a small inhibition of p53-/- xenografts [2]. In hypercholesterolemic animals, ibuprofen reduced the levels of total cholesterol, VLDL, LDL, triglycerides and atherogenic index. Also, ibuprofen inhibited COX enzymes and inhibited the generation of free radicals during prostaglandins synthesis, which reduced the levels of lipid peroxidation, superoxide dismutase [3]. In rats, ibuprofen (60 mg/kg) improved mechanical hyperalgesia through reducing central hyperexcitability [4].
References:
[1]. Kato M, Nishida S, Kitasato H, et al. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs: investigation using human peripheral monocytes. J Pharm Pharmacol, 2001, 53(12): 1679-1685.
[2]. Janssen A, Schiffmann S, Birod K, et al. p53 is important for the anti-proliferative effect of ibuprofen in colon carcinoma cells. Biochem Biophys Res Commun, 2008, 365(4): 698-703.
[3]. Dabhi JK, Solanki JK, Mehta A. Antiatherosclerotic activity of ibuprofen, a non-selective COX inhibitor--an animal study. Indian J Exp Biol, 2008, 46(6): 476-481.
[4]. Redondo-Castro E, Navarro X. Chronic ibuprofen administration reduces neuropathic pain but does not exert neuroprotection after spinal cord injury in adult rats. Exp Neurol, 2014, 252: 95-103.
| Cas No. | 15687-27-1 | SDF | |
| 别名 | 布洛芬; (±)-Ibuprofen | ||
| 化学名 | 2-[4-(2-methylpropyl)phenyl]propanoic acid | ||
| Canonical SMILES | CC(C)CC1=CC=C(C=C1)C(C)C(=O)O | ||
| 分子式 | C13H18O2 | 分子量 | 206.28 |
| 溶解度 | ≥ 10.3mg/mL in DMSO | 储存条件 | Store at RT |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 4.8478 mL | 24.2389 mL | 48.4778 mL |
| 5 mM | 0.9696 mL | 4.8478 mL | 9.6956 mL |
| 10 mM | 0.4848 mL | 2.4239 mL | 4.8478 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。